Morningstar Rating

Stock Research and Analysis

by Todd Wenning, CFA

Bulls Say

For certain medical treatments, traditional drug delivery via pill or syringe may not be ideal and there could be a migration toward inhaler and spray delivery in these areas.
Aptar has strong relationships with multinational consumer goods and pharmaceutical companies, and should thus find plenty of business in the emerging economies of Asia and Latin America.
Aptar's pharmaceutical segment will continue to generate generous amounts of free cash flow to help internally finance the group's international expansion plans and maintain its investment-grade credit rating. Read more 

Bears Say

There have been many dispensing innovations in recent years, particularly in the consumer goods space, so we may have passed the peak of the current replacement cycle.
Some pharmaceutical companies have taken drug delivery development in-house. If that trend intensifies, it could result in lower demand for Aptar's pharmaceutical products.
Aerosol valves have previously come under regulatory scrutiny and another round of similar regulations could inhibit the growth of Aptar's aerosol-based dispensing systems. Read more 

Management

We give Aptar an Exemplary stewardship rating, as we believe Aptar management has consistently made good use of shareholder capital. The most recent example of prudent capital allocation is the increased investment in its pharmaceutical division--by   Read more 

Profile

Aptar is a leading global supplier of dispensing systems such as aerosol valves, pumps, and closures to the consumer goods and pharmaceutical markets. With the bulk of its   Read more 

First Name
Last Name
Email Address
Zip Code
Create Password
Verify Password
(6-15 characters; case sensitive)

5 Dividend Stocks to Buy on Energy's Weakness 
Watch more 

Premium Membership

View all of our analyst reports with a free trial to Morningstar.com Premium.